Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool February 8, 2008 Brian Lawler	Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool July 25, 2008 Brian Lawler	Glaxo Changes Course Will a shift in strategy turn the drugmaker around?
The Motley Fool July 26, 2011 Cliff D'Arcy	GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool February 14, 2005 Stephen D. Simpson	Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
The Motley Fool January 28, 2011 Alan Oscroft	AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall.
The Motley Fool October 26, 2011 G. A. Chester	Glaxo Returns to Growth The U.K.'s No. 1 drug company still looks like a good value.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool October 23, 2008 Brian Orelli	Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool April 23, 2009 Brian Orelli	Hitting the Patent Cliff Early Glaxo is at the front edge of a patent cliff. But that means that when other drugmakers are hurting a few years down the road, Glaxo should be sitting pretty, seeing the fruits of all those partnerships it's investing in now.
The Motley Fool July 26, 2006 Stephen D. Simpson	GlaxoSmithKline: Reliable, Dependable ... Kinda Boring This is a good-but-not-great pharmaceutical giant with a good-but-not-great valuation. Investors, take note.
The Motley Fool May 1, 2008 Brian Lawler	Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind.
The Motley Fool February 12, 2004 Alyce Lomax	Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack.
The Motley Fool November 9, 2006 Brian Lawler	The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool February 8, 2006 Stephen D. Simpson	Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
The Motley Fool April 15, 2011 Brian Orelli	Shedding the Pounds Through Divestiture Glaxo plans to sell 19 OTC products.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
The Motley Fool September 15, 2006 Brian Lawler	Glaxo's Burgeoning Blockbuster With a deep drug pipeline filled with potential blockbusters for nearly every major disease, and an attractive 3% dividend yield, Glaxo makes a fine investment opportunity for investors willing to brave the pharmaceutical sector.
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
The Motley Fool April 28, 2005 Stephen D. Simpson	Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock.
The Motley Fool December 17, 2007 Brian Lawler	Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug.
The Motley Fool July 28, 2005 Stephen D. Simpson	Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool June 15, 2009 Brian Orelli	Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets.
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool September 11, 2008 Brian Orelli	Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded.
The Motley Fool February 5, 2009 Brian Orelli	Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool August 3, 2007 Brian Lawler	Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool April 23, 2008 Brian Lawler	Glaxo's Three-Quarter-Billion-Dollar Gamble Glaxo adds another development stage drugmaker to its portfolio. Investors take note.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool January 26, 2009 Brian Orelli	Have Drugs, Will Travel After buying Bristol-Myers Squibb's businesses in Egypt and Pakistan, GlaxoSmithKline is now off to Africa.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool December 17, 2008 Brian Orelli	A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off.
The Motley Fool February 22, 2010 Brian Orelli	Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.